James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $540.15, for a total value of $5,401,500.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,195,871.40. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, June 22nd, James Edgemond sold 8,750 shares of United Therapeutics stock. The shares were sold at an average price of $538.15, for a total value of $4,708,812.50.
• On Monday, June 15th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $549.17, for a total value of $5,491,700.00.
• On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00.
• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.50, for a total transaction of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total transaction of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.

United Therapeutics Price Performance

UTHR opened at $544.33 on Wednesday. The firm has a market capitalization of $23.11 billion, a PE ratio of 20.09, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. The business’s 50-day moving average is $563.19 and its two-hundred day moving average is $524.62. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the company posted $6.63 earnings per share. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its stake in United Therapeutics by 0.7% during the 1st quarter. Pacer Advisors Inc. now owns 243,545 shares of the biotechnology company’s stock valued at $144,417,000 after purchasing an additional 1,673 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of United Therapeutics by 2.8% in the first quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 29 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of United Therapeutics by 24.7% during the first quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $1,283,000 after purchasing an additional 428 shares during the period. Janus Henderson Group PLC boosted its position in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the last quarter. Finally, Bull Harbor Capital LLC purchased a new stake in United Therapeutics in the first quarter valued at approximately $494,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. Royal Bank Of Canada cut their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.